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Very-low-dose twice-daily aspirinmaintains platelet inhibition and improves
haemostasis during dual-antiplatelet therapy for acute coronary syndrome
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Abstract
Higher aspirin dosesmaybe inferior in ticagrelor-treated acute coronary syndrome (ACS) patients and
reducing bleeding risk whilst maintaining antithrombotic benefits could improve outcomes. We
characterized thepharmacodynamics of a novel dual-antiplatelet-therapy regimen consisting of very-
low-dose twice-daily (BD) aspirin with standard-dose ticagrelor. A total of 20 ticagrelor-treated ACS
patients entered a randomized crossover to take aspirin 20 mg BD (12-hourly) during one 14-day
period and 75mgonce-daily (OD) in the other. After 14 days of treatment, serum thromboxane (TX)B2
and light-transmittance aggregometry were assessed pre- and 2 h post-morning-dose, bleeding time
was measured post-dose, and TXA2 and prostacyclin stable metabolites were measured in urine
collected 2 h post-morning-dose. Data are expressed as mean ± SD. After 14 days treatment, serum
TXB2 levels were significantly greater 2 h post-dosing with aspirin 20 mg BD vs. 75 mg OD (3.0 ± 3.6
ng/mL vs. 0.8 ± 1.9 ng/mL; p = 0.018) whereas pre-dosing levels were not significantly different (3.5 ±
4.1 ng/mL vs. 2.5 ± 3.1 ng/mL, p= 0.23). 1-mmol/L arachidonic acid-induced platelet aggregationwas
similarly inhibited by both regimens pre-dose (8.5 ± 14.3% vs. 5.1 ± 3.6%, p = 0.24) and post-dose (8.7
± 14.2% vs. 6.6 ± 5.3%; p = 0.41). Post-dose bleeding time was shorter with 20mg BD (680 ± 306 s vs.
834 ± 386 s, p = 0.02). Urinary prostacyclin and TX metabolite excretion were not significantly
different. In conclusion, compared to aspirin 75 mg OD, aspirin 20 mg BD provided consistent
inhibition of platelet TXA2 release and aggregation, and improved post-dose hemostasis, in ticagre-
lor-treated ACS patients. Further studies are warranted to assess whether this regimen improves the
balance of clinical efficacy and safety.
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Abbreviations
8-iso-PGF2α: 8-iso prostaglandin 2α
ACS: acute coronary syndrome
BD: twice-daily
COX: cyclo-oxygenase
DAPT: dual antiplatelet therapy
MACE: major adverse cardiovascular events
OD: once-daily
PLATO: PLATelet inhibition and patient Outcomes
PGI2: prostacyclin
TX: thromboxane
Introduction
The combination of the irreversible cyclo-oxygenase (COX)
inhibitor aspirin (acetylsalicylic acid) 75–100 mg once-daily
(OD) and the P2Y12 inhibitor ticagrelor 90 mg twice-daily
(BD) represents a standard recommended regimen of dual anti-
platelet therapy (DAPT) in acute coronary syndromes (ACS) [1–
4]. The PLATelet inhibition and patient Outcomes (PLATO)
study showed that DAPT with aspirin and ticagrelor was super-
ior to the previous standard regimen of aspirin and clopidogrel
in ACS, reducing the incidence of major adverse cardiovascular
events (MACE). Despite such potent antiplatelet therapy, the
residual MACE risk remains around 10% at 1 year [5].
Continuing DAPT with aspirin and reduced-dose ticagrelor long-
term in stable high-risk individuals further decreases the riskofMACE
compared with aspirin alone [6]. However, increasing the potency or
duration ofDAPTalso leads to increased bleeding,which is associated
not only with higher mortality but also patient distress, inconvenience,
and premature discontinuation, even if events are considered minor or
trivial by clinicians [7,8]. Concern about bleeding risk may, therefore,
dissuade clinicians from recommending DAPT, particularly in the
long-term, to the potential detriment of high-risk patients.
Color versions of one or more of the figures in the article can be found
online at www.tandfonline.com/iplt.
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Further subgroup analysis of the PLATO study suggested that
doses of aspirin ≥ 300 mg were associated with reduced benefit of
ticagrelor over clopidogrel and, as a result, daily aspirin doses
>100 mg are not recommended when used in DAPT [9,10].
Aspirin and ticagrelor have additive antithrombotic effects [11].
Whilst ticagrelor inhibits the platelet adenosine diphosphate P2Y12
receptor, aspirin’s action relates to its ability to irreversibly inhibit
platelet COX-1, thus reducing prothrombotic eicosanoid TXA2
production. Aspirin can achieve almost-complete (≥95%) inhibi-
tion of TXA2 biosynthesis in healthy subjects at repeated daily
doses as low as 20–30 mg [12–14]. At doses above 300 mg, aspirin
also inhibits COX-2 in humans, a key enzyme in the pathway of
constitutive, vascular-protective prostacyclin (PGI2) release by the
endothelium [12,15]. Inhibition of COX-2 and PGI2 biosynthesis
may be counterproductive in patients with ACS: both traditional
and COX-2-selective nonsteroidal anti-inflammatory drugs are
associated with an increased risk of MACE [16–18]. There is also
evidence from animal studies that ticagrelor may beneficially
induce COX-2 and endothelial nitric oxide synthase through an
adenosine-dependent mechanism, which may limit myocardial
infarct size through synergistic antiplatelet and vasodilatory effects
of PGI2, nitric oxide and P2Y12 inhibition [19–21]. Therefore,
inhibition of COX-2 by high-dose aspirin may compromise the
beneficial effects of ticagrelor on this pathway.
Aspirin dosing frequency may also influence pharmacodynamic
efficacy: OD aspirin administration may be insufficient to maintain
consistency of platelet inhibition over 24 h in patients with higher
platelet turnover, including smokers and thosewith obesity or diabetes
mellitus, or in individuals undergoing procedural intervention [22–
27]. Multiple daily-dosing regimens of aspirin have been shown to
improve consistency of pharmacodynamic effect, not only in condi-
tions with extreme acceleration of platelet turnover, such as essential
thrombocythemia [28–30], but also in patients with ischemic heart
disease [25,27,31–33] when administered as single antiplatelet ther-
apy. However, such regimens of aspirin have not been studied in those
receiving dual antiplatelet therapy (DAPT) with ticagrelor, which is
already given BD, in whom the overall pharmacodynamic profile of
DAPT may potentially be improved by BD aspirin dosing.
An ideal regimen of aspirin and ticagrelor would be one that
maintains the anti-ischemic benefit of DAPT through effective and
steady inhibition of platelet COX-1 and P2Y12, ensures consistency of
effect across the dosing interval, avoids inhibition of vasoprotective
COX-2-dependent PGI2 biosynthesis and has minimized effects on
hemostatic capacity. We hypothesized that ticagrelor administered
with a lower-than-standard, multiple-daily dose of aspirin establishes
a beneficial hemostatic profile and sowe investigated a novel regimen
of aspirin 20 mg BD and ticagrelor 90 mg BD in patients treated
for ACS.
Methods
In the WILL lOWer dose aspirin be more effective in ACS?
(WILLOW ACS) study, 20 patients with a history of recent ACS
established on ticagrelor-based DAPT provided informed consent to
participate in this study. To proceed to randomization, participants
were required to meet the following inclusion criteria: male or female
aged greater than 18 years; previous diagnosis of acute coronary
syndrome greater than 30 days and less than 10 months before enrol-
ment; and receiving DAPT with aspirin 75 mg OD and ticagrelor
90mgBD. Participants were excluded if theymet any of the following
criteria: indication for DAPT other than ischaemic heart disease;
percutaneous coronary intervention with drug-eluting or bare-metal
stent(s) within 30 days prior to randomization; any history of stent
implantation to the left main coronary artery; any history of stent
thrombosis during DAPT; further planned coronary revascularization
procedure; any planned surgery or other procedure that might require
suspension or discontinuation of DAPT expected to occur within 3
months of randomization; prior intention by patient or physician to
discontinue aspirin and/or ticagrelor within the study period; doses of
aspirin and ticagrelor other than 75 mg OD and 90 mg BD, respec-
tively; treatment or planned treatment with antiplatelet medication
apart from aspirin or ticagrelor (eg. clopidogrel, prasugrel, dipyrida-
mole or ticlopidine); currently receiving a diuretic agent (including
loop, thiazide or potassium-sparing diuretics) as these may affect
prostanoid assays; any ACS event within 30 days prior to randomiza-
tion; most recent ACS event greater than 10 months prior to rando-
mization; current or planned use of an oral anticoagulant (e.g.
warfarin, dabigatran, rivaroxaban, apixaban), parenteral anticoagulant
(e.g. unfractionated heparin, low-molecular-weight heparin, bivaliru-
din), glycoprotein IIb/IIIa inhibitor (e.g. abciximab, tirofiban) or
fibrinolytic agent (e.g. tissue plasminogen activator); or requiring, or
likely to require, treatment with a nonsteroidal anti-inflammatory
drug, including intermittent/as required use; history of acute or
chronic liver disease (e.g. cirrhosis), end-stage renal failure requiring
dialysis, alcohol or drug abuse, defined as regular use of an illicit
substance for recreational purposes or regular consumption of greater
than 50 units (males) or 35 units (females) of alcohol per week in the
last year; any comorbidity associated with life expectancy less than
1 year; or any other condition deemed by the investigator to affect
hemostasis, coagulation, bleeding risk or ability to comply with the
study protocol. To prevent interaction with ticagrelor treatment, those
receiving a strong inhibitor of cytochrome P450 3A (e.g. ketocona-
zole, itraconazole, voriconazole, telithromycin, clarithromycin, nefa-
zadone, ritonavir, saquinavir, nelfinavir, indinavir, atanazavir, or over
1 L daily of grapefruit juice), simvastatin or lovastatin at doses higher
than 40 mg daily, a cytochrome P450 3A substrate with a narrow
therapeutic index (e.g. cyclosporine or quinidine), or a strong inducer
of cytochrome P450 3A (e.g. rifampin, rifabutin, phenytoin, carbama-
zepine, phenobarbital) were also excluded.
Females of child-bearing potential were similarly prevented from
proceeding to randomization unless they had a negative pregnancy test
at screening and were willing to use protocol-defined effective contra-
ception for the duration of treatment with study medication.
Study Design
After collection of baseline demographic and clinical information,
participants were randomized using opaque-sealed envelopes
shuffled by an individual outside of the research team, in a 1:1
ratio, to one of two sequences of different regimens of soluble
aspirin in an open-label crossover design (Figure 1):
(1) Aspirin 20 mg BD (12-hourly, morning and evening) for 14
days then aspirin 75 mg OD (in the morning) for 14 days.
(2) Aspirin 75 mg OD (in the morning) for 14 days then aspirin
20 mg BD (12-hourly, morning and evening) for 14 days.
All other usual medications, including ticagrelor 90 mg BD (12-
hourly, morning and evening), were continued throughout the study in
all participants.
Blood samples for serum thromboxane B2 (TXB2) and light
transmittance aggregometry (LTA), urine samples for PGI2 metabo-
lite and TX metabolite, and bleeding time measurement using
a standard lancet method were obtained at the following time points:
(1) After 14 days of study medication, pre-aspirin dose (platelet
function and serum TXB2), representing trough effect, and 2
h post-dose (platelet function, serum TXB2, urinary prosta-
noids and bleeding time), representing peak effect.
(2) After 28 days (end of second studymedication period) pre-aspirin
dose (platelet function and serum TXB2) and 2 h post-dose
(platelet function, serum TXB2, urinary prostanoids and bleeding
time).
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Treatment periods of 14 days ensured that steady-state effects of
aspirin were reached, whilst sampling 2 h after aspirin dose meant it
could be confidently asserted that the time to maximal plasma con-
centration had elapsed, and so peak effects on platelet function, which
persist beyond this point, were being observed [34,35].
Clinical outcomes were reviewed and adverse events recorded at
14 and 28 days. At the 28-day visit, patients with an indication for
ongoing DAPTwere transitioned to standard care with aspirin 75 mg
OD and arrangements for ongoing supply of this medication were
ensured. A telephone contact was made at 14 days after study medica-
tion discontinuation to ensure the successful transition to standard care
and to record any adverse events for safety monitoring. Vital signs,
physical examination findings and concurrent medications were
recorded at each timepoint. On the last day of each medication period,
participants were asked to take their ticagrelor on waking but delay
aspirin until they attended for the study visit.
Drug Supply and Accountability
To ensure accurate titration of aspirin doses, a fully soluble aspirin
lysine preparation was used (Aspegic; Sanofi-Aventis, Machelen,
Belgium). Each “100 mg” sachet contained 180 mg of aspirin lysine,
including 100 mg of acetylsalicylic acid (aspirin). Participants were
provided with tuition, illustrated written instructions and dosing
equipment. They were asked to dissolve the whole of a 100mg aspirin
sachet in 100 mL of drinking water, measured in a graduated beaker
(Sarstedt, Nümbrecht, Germany), stirring for 30 s to ensure full
dissolution. To prepare 20 mg, they were asked to withdraw 20 mL
of the solution using a marked syringe (Beckton-Dickinson, Franklin
Lakes, New Jersey, USA) and ingest that amount, discarding the
remainder. To dispense 75 mg they were asked to withdraw 25 mL
and ingest the remainder. A new sachet was used for each dose to
minimize drug hydrolysis once in solution.
Participants were provided with a medication diary to record
times of aspirin and ticagrelor administration during the study, in
order to assess compliance with study medication, which was also
measured by counting returned aspirin sachets.
Serum Thromboxane B2
Whole blood was collected into 5 mL serum separator tubes
(Becton-Dickinson, New Jersey, USA) and immediately placed
into a water bath, preheated to 37oC, for 30 min, as previously
described [36,37]. Tubes were then centrifuged, serum was drawn
off and stored at −80oC until analysis. Levels of the nonenzy-
matic metabolite of TXA2, TXB2, which in contrast to its pre-
cursor is highly stable in serum and therefore more suitable for
measurement as a marker of platelet COX-1 activity [37], were
estimated using a commercially available enzyme-linked immu-
nosorbent assay (Cayman Chemical, Ann Arbor, USA). Samples
were assessed twice and repeated if significant discrepancies were
detected between the measurements. Interplate coefficient of
variability (CV) for a standard mid-range concentration of TXB2
(62.5 pg/mL) was 14.3% in our laboratory, and mean intraplate
CV was 9.5%.
Light Transmittance Aggregometry
A broad assessment of platelet reactivity was made pre- and 2
h post-dose at the end of each treatment period using 6-min LTA
with arachidonic acid (0.1, 0.3 and 1.0 mmol/L), collagen (1, 4
and 16 µg/mL) and adenosine diphosphate (20 µmol/L) as ago-
nists (PAP-8 v2.0, Bio/Data Corporation, Horsham, PA, USA;
stir speed 1200 rpm). Maximum aggregation response, adjusted
for baseline aggregation, was recorded for each agonist. Samples
were assessed in duplicate, taking the mean value for analysis,
and repeated if a discrepancy of >10% was observed between
the readings.
Bleeding Time
Hemostasis was assessed using a standard lancet method
(Haemolance Max Flow Plus, HTL-STREFA S.A., Poland).
A calibrated sphygmomanometer cuff (Welch Allyn,
Buckinghamshire, UK) was inflated around the upper arm to 40
mmHg and three incisions made on the volar aspect of the fore-
arm. Each puncture site was checked for hemostasis every 30
s using filter paper (Whatman Grade 1, GE Healthcare, Little
Chalfont, UK) until bleeding stopped or 30 min was reached.
A mean of bleeding times was calculated. The method was
validated in healthy volunteers receiving no medication (n = 5).
Urinary Prostanoids
Midstream urine was collected around 2 h after the last study
medication dose of each treatment period, centrifuged to remove
any cellular material and then stored at −80oC prior to analysis.
Urine PGI2 metabolite (2,3-dinor-6-keto prostaglandin F1α, PGI2
metabolite) was measured by gas chromatography-mass spectro-
metry, as previously described [38,39].
Urinary TX metabolite (11-dehydro-TXB2) and 8-iso prosta-
glandin F2α (8-iso PGF2α), a marker of oxidant stress, were
measured by previously validated immunoassays [40]. Urinary
prostanoids were corrected for urinary creatinine levels, measured
by the Department of Laboratory Medicine, Northern General
Figure 1. Overall design of the WILL lOWer dose aspirin be more effective in ACS? (WILLOW ACS) study. ACS, acute coronary syndrome; BD,
twice daily; mg, milligrams; OD, once daily; R, point of randomization.
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Hospital, Sheffield, using a clinically accredited automated assay
(Roche, Basel, Switzerland).
Fibrin Clot Dynamics
Aspirin is known to affect fibrin clot dynamics [41,42]. To study
the effects of the two aspirin regimens on clot formation and lysis,
high-throughput turbidimetric analysis was performed as
described and validated elsewhere [43–47]. Briefly, plasma sam-
ples were mixed with standard lysis and activation mixes to form
acellular clots. Serial absorbance was measured using an auto-
mated plate reader until lysis was achieved. Variables recorded
were maximum absorbance (a representation of fibrin clot turbid-
ity), lag time (time from addition of clot activation mix to the start
of clot formation) and lysis time (time taken for turbidity to drop
by 50% from maximum as a measure of lysis potential).
Safety Monitoring
Although primarily a pharmacodynamic study, we monitored safety
throughout: the primary safety objective was to estimate the inci-
dence of PLATO-defined major plus minor bleeding at 14 days in
patients treated with ticagrelor and either one of the two aspirin
dosing regimens [5]. Additionally, all adverse events (AEs) occurring
between randomization and the telephone call 14 days after comple-
tion of study treatment were recorded. Serious adverse events (SAEs)
were defined as any that resulted in death, was life-threatening,
required hospitalization or prolongation of existing hospitalization,
resulted in persistent disability or incapacity or consisted of
a congenital abnormality or birth defect. Causality was assessed by
the investigators. All AEs were followed up until resolved or stable.
Statistical Analysis
The primary endpoint of the study was 2-h post-dose serum TXB2,
compared within patients between the two dosing regimens by
a paired t-test. Based on our previous data showing a mean serum
TXB2 level of 2.9 ng/mL following ticagrelor 90 mg and aspirin 75
mg maintenance doses [36], we estimated that 20 patients entering
the crossover design would have 80% power to detect a difference of
1.7 ng/mL in post-dose serum TXB2 between the regimens with
alpha of 0.05. Based on previous data showing a mean circulating
TXB2 level in non-aspirin-treated individuals (both healthy volun-
teers and patients with atherosclerotic disease) of around 45 ng/mL
[15,48], we estimated that a difference of 1.7 ng/mL would repre-
sent a change of 3.8% in TXB2 inhibition.
Statistical analysis was performed using GraphPad PRISM ver-
sion 7.03 (GraphPad Software Inc., La Jolla, CA, USA), using an
alpha of 0.05 to determine significance. Continuous data are pre-
sented as mean ± standard deviation (SD). Where data were sig-
nificantly skewed (as was the case for TXB2), log transformation
was performed prior to analysis. Analysis was by intention to treat.
Study Oversight
Approval to conduct the study was granted by the Sheffield
National Research Ethics Service Committee, by the
Medicines and Healthcare products Regulatory Authority and
by the Health Research Authority prior to commencement of
research activities, which were monitored by the Sheffield
Teaching Hospitals National Health Service Foundation
Trust Clinical Research Office. The study was registered
with clinicaltrials.gov (NCT02741817) before commencing
any research activity.
Results
Twenty participants (16 males and 4 females) were randomized
between July and December 2016, and all completed the study.
Baseline characteristics are shown in Table I. Sampling times,
compliance and physiological observations were similar between
the two treatment regimens (Table II).
Serum TXB2
At steady state, mean (± SD) serum TXB2 levels 2 h post-dose were
significantly greater when receiving 20 mg BD when compared to
75 mg OD (3.03 ± 3.64 ng/mL vs. 0.83 ± 1.93 ng/mL, p = 0.018)
(Table III, Figure 2(a)) and there was no significant difference
between the regimens at pre-dose, which corresponds to the trough
effect (3.51 ± 4.07 ng/mL vs. 2.48 ± 3.14 ng/mL, p = 0.23) (Table
III, Figure 2(a)). There was no evidence of a carryover effect
between the dosing regimens: no significant differences in pre- or
post-dose TXB2 measurements were observed between the partici-
pants who received 20 mg BD in the first period vs. the second (pre-
Table I. Baseline demographics of the 20 randomized patients.
Characteristic –
Sex, male, n (%) 16 (80%)
Age, years, mean (SD) 64.3 (11.9)
Race –
Caucasian 18 (90%)
Black 2 (10%)
Other 0 (0%)
Height, cm, mean (SD) 171.4 (10.4)
Weight, kg –
Mean (SD) 83.6 (15.5)
Median (range) 86 (55–106)
BMI, kg/m2 –
Mean (SD) 28.3 (3.9)
Median (range) 28.6
(22.6–37.1)
Systolic BP, mmHg, mean (SD) 134.8 (20.1)
Diastolic BP, mmHg, mean (SD) 71.7 (11.7)
Pulse rate, bpm, mean (SD) 59.2 (5.6)
Diagnosis –
STEMI 7 (35%)
NSTEMI 13 (65%)
Unstable angina 0 (0%)
Management of ACS –
PCI 16 (80%)
CABG 0 (0%)
Conservative 4 (20%)
Smoking status -
Current 2 (10%)
Past 11 (55%)
Never 7 (35%)
Diabetes mellitus 3 (15%)
Hypertension 11 (55%)
Hypercholesterolaemia 9 (45%)
Time from ACS event to randomization, days, mean
(SD)
123.8 (82.8)
Concurrent medication –
Beta-blocker 17 (85%)
ACE inhibitor/ARB 19 (95%)
Statin 19 (95%)
Regular nitrate 1 (5%)
Nicorandil 1 (5%)
Proton pump inhibitor 13 (65%)
ACE, angiotensin converting enzyme; ACS, acute coronary syndrome;
ARB, angiotensin receptor blocker; CABG, coronary artery bypass
grafting; NSTEMI, non-ST elevation myocardial infarction; PCI, percu-
taneous coronary intervention; STEMI, ST-elevation myocardial infarc-
tion; UA, unstable angina
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dose p = 0.768, 2 h post-dose p = 0.774, data not shown) and
between those who received 75 mg OD in the first vs. the second
(pre-dose p = 0.907, post-dose p = 0.914, data not shown).
Bleeding Time
Bleeding time measured 2 h post-dose in each treatment period
was significantly shorter when receiving aspirin 20 mg BD
compared to 75 mg OD (679.5 ± 305.5 vs. 833 ± 385.7 s, p =
0.04), a mean reduction of 154.5 s (18.5%) (Table III, Figure 2
(b)). For comparison, mean ± SD bleeding time in five healthy
drug-free volunteers was 342 ± 72 s, with a mean intrasubject
variation of 24 s (7%).
Light Transmittance Aggregometry
There were no significant differences in arachidonic acid- or
adenosine diphosphate-induced maximum aggregation responses
between the regimens (Table III, Figure 3).
Two-hours post-dose maximum aggregation responses to col-
lagen 1 and 4 µg/mL (but not 16 µg/mL) were greater when
receiving aspirin 20 mg BD compared to 75 mg OD (mean ±
SD: 20 mg BD 16.5 ± 15.6% vs. 75 mg OD 9.0 ± 5.7%, p = 0.03;
and 20 mg BD 44.6 ± 23.3 vs. 75 mg OD 29.6 ± 14.9%, p =
0.007 for collagen 1 and 4 µg/mL, respectively). Pre-dose max-
imum aggregation to collagen 1 µg/mL (26.3 ± 20.3 vs. 15.5 ±
9.4%, p = 0.03), but not 4 or 16 µg/mL, was greater when
receiving aspirin 20 mg BD (Table III, Figure 3). Given the
Table II. Comparison of study medication period duration, sampling times and compliance between the 20 mg BD and 75 mg OD aspirin regimens.
Values are shown as mean ± SD and p values were generated by paired t-tests.
– 20 mg BD 75 mg OD p value
Time from aspirin dose to post-aspirin venepuncture (mins) 124.7 ± 18.2 123.1 ± 10.2 0.68
Time from last ticagrelor dose to pre-aspirin venepuncture (mins) 214.0 ± 208.5 184.9 ± 160.2 0.36
Time from aspirin dose to bleeding time measurement (mins) 122.2 ± 21.0 122.8 ± 19.6 0.88
Time from last aspirin dose to collection of urine sample (mins) 133.9 ± 24.7 136.2 ± 24.6 0.76
Time of aspirin dose on day of sampling from previous dose (hrs) 13.7 ± 2.4 26.2 ± 1.8 NA
Compliance with aspirin therapy (% of doses taken) 99.9 ± 0.7 100.0 ± 0.0 0.33
Compliance with ticagrelor therapy (% of doses taken) 100.0 ± 0.0 99.7 ± 1.3 0.33
Time on study medication (days) 14.95 ± 2.0 14.80 ± 1.47 0.55
Systolic BP (mmHg) 127.3 ± 12.9 128.8 ± 15.5 0.67
Diastolic BP (mmHg) 72.2 ± 10.2 71.1 ± 10.2 0.53
Heart rate (bpm) 60.7 ± 6.0 62.3 ± 10.3 0.49
BD, twice daily; BP, blood pressure; bpm, beats per minute; hrs, hours; mmHg, millimeters of mercury; Mins, minutes; NA, not applicable; OD, once daily
Table III. Results of analyses of pharmacodynamic endpoints during each aspirin dosing regimen at steady state. Values shown are mean ± SD.
p values were generated from paired t-tests.
– 20 mg BD 75 mg OD p value
PRE-DOSE (TROUGH EFFECT)
Serum TXB2 (ng/mL) 3.51 ± 4.07 2.48 ± 3.14 0.23
Light transmittance aggregometry—maximum aggregation (%)
Agonist [Agonist] –
AA (mmol/L) 0.1 2.5 ± 1.8 2.4 ± 1.6 0.62
0.3 2.2 ± 1.3 1.7 ± 1.5 0.10
1 8.7 ± 14.2 6.6 ± 5.3 0.41
Collagen (µg/mL) 1 26.3 ± 20.3 15.5 ± 9.4 0.03
4 57.0 ± 15.7 51.0 ± 18.1 0.16
16 72.1 ± 11.8 73.5 ± 9.1 0.60
ADP (µmol/L) 20 44.6 ± 11.7 41.5 ± 12.0 0.21
POST-DOSE (PEAK EFFECT)
Serum TXB2 (ng/mL) 3.03 ± 3.64 0.83 ± 1.93 0.018
Urinary TxM (pg/mg creatinine) 430.0 ± 269.7 371.5 ± 176.6 0.17
Urinary PGI-M (pg/mg creatinine) 109.9 ± 143.3 86.68 ± 54.58 0.41
Urinary 8-iso-PGF2α (pg/mg creatinine) 2713 ± 1534 2834 ± 1945 0.77
Bleeding time (s) 679.5 ± 305.5 833.9 ± 385.7 0.04
Light transmittance aggregometry—maximum aggregation (%)
Agonist [Agonist] –
AA (mmol/L) 0.1 2.3 ± 1.5 2.6 ± 1.5 0.50
0.3 2.1 ± 1.6 1.7 ± 0.9 0.23
1 8.5 ± 14.3 5.1 ± 3.6 0.24
Collagen (µg/mL) 1 16.5 ± 15.6 9.0 ± 5.7 0.03
4 44.6 ± 23.3 29.6 ± 14.9 0.007
16 65.6 ± 12.0 58.4 ± 13.7 0.11
ADP (µmol/L) 20 40.9 ± 15.5 40.6 ± 12.1 0.86
AA, arachidonic acid; ADP, adenosine diphosphate; BD, twice-daily; PGI-M, prostacyclin metabolite; OD, once-daily; s, seconds; TXB2,
thromboxane B2
DOI: https://doi.org/10.1080/09537104.2019.1572880 Very-low-dose twice-daily aspirin in ACS 5
universally low, though expected, responses to arachidonic acid,
the efficacy of the agonist was tested in drug-free platelet-rich
plasma from healthy volunteers (n = 8): mean (± SD) maximum
aggregation in response to stimulation with 1 mmol/L arachidonic
acid was 79.1 ± 7.4%.
Urinary Prostanoids
Urinary TX metabolite, which represents COX-1 activity over
a broader time range than serum TXB2, showed no significant
difference comparing BD vs. OD regimens (430.0 ± 269.7 vs.
371.5 ± 176.6 pg/mg creatinine, p = 0.17 for paired comparison).
Figure 2. Serum TXB2 (a) and bleeding time (b) in ACS patients receiving two regimens of aspirin and ticagrelor in the WILLOW ACS study. Bars
represent mean + SD. Dots and lines represent paired values for the individual participants. p values shown were generated by paired t-tests between
the groups (see text and tables for further details). BD, twice-daily; OD, once-daily s, seconds; sTXB2, serum thromboxane B2. the groups (see text
and tables for further details). Scale on the y-axis in Figure 2(a) is logarithmic. BD, twice-daily; OD, once-daily s, seconds; TXB2, thromboxane B2.
Figure 3. Maximum platelet aggregation responses to arachidonic acid, adenosine diphosphate and collagen assessed by light transmittance
aggregometry pre- and post-aspirin dose at the end of each treatment period in the WILLOW ACS study. Bars indicate mean + SD. p values were
generated using prespecified paired t-tests. AA, arachidonic acid; ADP, adenosine diphosphate; BD, twice-daily; OD, once-daily.
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Urine PGI-M and 8-iso-PGF2α levels did not significantly differ
between the two groups (Table III, Figure 4).
Fibrin Clot Parameters
Given the importance of fibrin network lysis in cardiovascular out-
come following acute coronary syndrome [47], and the effects of
aspirin on the fibrin clot [41], we studied potential differences in
a number of fibrin clot properties comparing the two different dosing
regimens of aspirin. We found no significant differences in lag time (a
measure of clotting tendency), clot maximum absorbance (a measure
of clot density and fiber thickness) or lysis time (a measure of
resistance of clot to breakdown) between the regimens pre- or post-
aspirin dosing in the two groups studied (supplementary material).
Safety
There were no PLATO-defined major or minor bleeding events and
no SAEs occurred during the study, including any thrombotic events.
Two participants suffered trivial bleeding events during the aspirin
75 mg OD period, compared to none whilst receiving aspirin 20 mg
BD (Supplementary Table I). No participant stopped studymedication
prematurely.
Effect of Weight and Body Mass Index
Study participants had a median enrolment weight of 86 kg (range
55–106) and body mass index (BMI) of 28.6 kg/m2 (22.6–37.1).
There were no significant correlations between body weight or BMI
and TXmetabolite or PGI2metabolite when receiving either the novel
or standard regimen (Supplementary Figure 1), suggesting the effi-
cacy of the novel regimen was maintained across the range of weight
and BMI.
Discussion
DAPT with aspirin and ticagrelor represents a standard main-
tenance antithrombotic therapy that is recommended as first-line
treatment following ACS [3,4,49]. Typically given for at least
1 year, continuation for longer remains an effective strategy for
preventing MACE in high-risk patients but comes at the price of
increased bleeding [6]. Even though the overall balance of
mortality risks appears to favor use of longer-term ticagrelor-
based DAPT in high-risk patients [50–52], clinicians and
patients alike may be reluctant to extend DAPT therapy due to
the bleeding risk. It has been proposed that aspirin can safely be
stopped in ticagrelor-treated patients with a history of percuta-
neous coronary intervention [53], an approach tested in the
recently reported GLOBAL LEADERS study, which showed
that 1 month of DAPT followed by 23 months of ticagrelor
monotherapy was not superior to 12 months of DAPT followed
by 12 months of aspirin monotherapy, although this was limited
by heterogeneity of P2Y12 receptor antagonists in the control
group [54]. Even if ticagrelor monotherapy is effective in pre-
venting stent thrombosis, there are likely to remain a significant
group of patients at high risk of ongoing native plaque rupture
events in whom DAPT is needed to optimize protection against
future MACE.
Strategies maintaining the combined antithrombotic effect of
DAPT, whilst reducing bleeding tendency, therefore have the
potential to improve overall clinical outcomes. We have shown
that a novel regimen of very-low-dose BD aspirin given to tica-
grelor-treated ACS patients broadly maintains the inhibitory effects
of aspirin on TXA2 synthesis and arachidonic acid-induced platelet
activation, but reduces peak inhibition and is associated with
a significant reduction in bleeding time (Figure 5). It remains to
be determined whether this will translate into a reduction in clinical
bleeding events, but similar doses have previously been shown to
have clinical antithrombotic efficacy. The European Stroke
Prevention Study 2 investigated a similar very-low-dose, BD
aspirin regimen (25 mg BD) alone or in combination with another
antiplatelet drug (dipyridamole) in 6602 stroke patients, showing
a significant benefit of BD aspirin, alone or in combination, vs.
placebo in preventing recurrent cerebrovascular events [55]. Giving
aspirin BD may also improve symmetry of DAPT effect when
given with ticagrelor, which is also given BD, and may simplify
drug intake, including the possibility of developing a combination
tablet. This might help to address the under-recognized issue of
treatment compliance that can limit the efficacy of treatment
Figure 4. Urinary levels of TX metabolite, PGI2metabolite 8-iso-PGF2αmeasured at the end of each treatment period. Bars represent mean + SD. Dots and
lines represent paired values for the individual participants. p values shown were generated by paired t-tests between the groups. Scale on the y-axis is
logarithmic. 8-iso-PGF2α, 8-iso prostaglandin F2α; BD, twice- daily; PGI-M, prostacyclin metabolite; OD, once-daily; TxM, thromboxane metabolite.
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strategies in coronary artery disease patients [56], and can be
improved by reducing the number of tablets they receive [57].
The use of very-low-dose twice-daily aspirin in this setting is
only considered feasible when given in combination with ticagrelor
which, in contrast to older drugs, provides potent and reliable P2Y12
inhibition [58]. P2Y12 inhibitors reduce AA-induced platelet aggre-
gation independently of aspirin [59], meaning there may be
a rationale for reducing the intensity of aspirin therapy. However,
the results of our study also illustrate the fact that aspirin continues to
provide additional antiplatelet effects even in the presence of potent
P2Y12 inhibition, given that we saw differences in TX-related bio-
markers and platelet function between the two dosing regimens at 2
h post-dose. This is consistent with previous studies of the relation-
ship between aspirin and P2Y12 receptor inhibition or deficiency
[60]. Hence, there is justification for an approach that continues to
include aspirin but seeks to reduce its intensity to improve hemos-
tasis whilst maintaining adequate levels of platelet inhibition.
In pre-dose samples, we saw similar levels of overall platelet
inhibition with the two regimens, but it is possible there may be
differences at the platelet level in the pattern of inhibition between
the two regimens at this timepoint given that some newly formed
platelets will be more rapidly exposed to aspirin with the BD regi-
men. Even a small number of uninhibited platelets can form the
basis for thrombosis [61]. However, the clinical efficacy and safety
of a BD aspirin regimen remains to be explored.
The study was limited by a small sample size and therefore was
unable to determine whether the very-low-dose aspirin regimen
significantly improves in vivo prostacyclin biosynthesis so this
will require assessment in a larger study. The goal of the current
study was to provide reassurance from a pharmacodynamic study
that such a larger study is appropriate. Similarly, we only compared
one novel regimen with standard therapy, rather than including
multiple permutations; however, our results suggest that aspirin
20 mg BD and ticagrelor 90 mg BD achieve our goal of reducing
peak-trough variation in effect and improving hemostasis.
We saw no significant correlation between weight or BMI and
COX-1 inhibition in the present study (supplementary material) but
lacked sufficient numbers of obese patients, with or without diabetes,
to determine levels of COX-1 inhibition in these individuals who tend
to have diminished response to low-dose aspirin [62]. Consequently,
further pharmacodynamic studies focussing on obese or diabetes
patients are required to understand how aspirin regimens may poten-
tially bemodified in these individuals when combined with ticagrelor.
In conclusion, aspirin dose modification represents a novel and
feasible strategy to be investigated for optimizing the balance of
antithrombotic benefits and bleeding-related risks in ticagrelor-
treated ACS patients, and demands further study to determine
whether this translates into improvements in net clinical outcomes.
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